☆ 3.9 Article

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary

JOURNAL OF ONCOLOGY PRACTICE (2018)

Get Full Text
Add to Collection

Journal

JOURNAL OF ONCOLOGY PRACTICE
Volume 14, Issue 4, Pages 247-+

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JOP.18.00005

Keywords

-

Categories

Oncology

Funding

  1. Bristol-Myers Squibb
  2. Merck
  3. AstraZeneca
  4. Incyte
  5. Five Prime Therapeutics
  6. Janssen Oncology
  7. F Hoffman-La Roche
  8. Seattle Genetics
  9. Pfizer
  10. Agensys
  11. Corvus Pharmaceuticals
  12. Trillium Therapeutics
  13. Novartis

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.